Institute of Organic Chemistry and Biochemistry AS CR vvi:製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Institute of Organic Chemistry and Biochemistry AS CR vvi - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C9410
◆発行会社(調査会社):GlobalData
◆発行日:2018年11月
◆ページ数:17
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:チェコ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Institute of Organic Chemistry and Biochemistry AS CR vvi (IOCB) is a research institute that offers organic chemistry and biochemistry for medical and environmental applications. The institute’s scientific research includes the fields of physico-organic chemistry and biochemistry, molecular and cellular biology, computational chemistry, medicinal chemistry, and molecular pharmacology, among others. It offers its research in medical and environmental fields aims on development of new synthetic, analytical and computational procedures, biotechnological, and the development of functional molecules. IOCB also provides its research in the study of the structure, properties and biological activity of substances, nucleic acids, chemistry and biochemistry of peptides, proteins, natural materials and their components and analogues. The institute offers its services across the Czech Republic. IOCB is headquartered in Prague, the Czech Republic.

Institute of Organic Chemistry and Biochemistry AS CR vvi – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Institute of Organic Chemistry and Biochemistry AS CR vvi, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Institute of Organic Chemistry and Biochemistry AS CR vvi, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Institute of Organic Chemistry and Biochemistry AS CR vvi, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Institute of Organic Chemistry and Biochemistry AS CR vvi, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Institute of Organic Chemistry and Biochemistry AS CR vvi, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Institute of Organic Chemistry and Biochemistry AS CR vvi, Pharmaceuticals & Healthcare, Deal Details 10
Partnerships 10
Institute of Organic Chemistry and Biochemistry Enters into Co-Development Agreement with Johns Hopkins Medicine 10
Enamine Enters Into Co-Development Agreement With MRC LMB And IOCB For Rhomboid Protease Inhibitors 11
Licensing Agreements 12
Dracen Pharma Enters into Licensing Agreement with Johns Hopkins University and Institute of Organic Chemistry 12
Institute of Organic Chemistry and Biochemistry AS CR vvi – Key Competitors 13
Institute of Organic Chemistry and Biochemistry AS CR vvi – Key Employees 14
Institute of Organic Chemistry and Biochemistry AS CR vvi – Locations And Subsidiaries 15
Head Office 15
Recent Developments 16
Government and Public Interest 16
May 15, 2018: A new inhibitor of protein aggregation associated with Parkinson’s disease from Dmytro Yushchenko Group 16
Appendix 17
Methodology 17
About GlobalData 17
Contact Us 17
Disclaimer 17

List of Tables
Institute of Organic Chemistry and Biochemistry AS CR vvi, Pharmaceuticals & Healthcare, Key Facts 2
Institute of Organic Chemistry and Biochemistry AS CR vvi, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Institute of Organic Chemistry and Biochemistry AS CR vvi, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Institute of Organic Chemistry and Biochemistry AS CR vvi, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Institute of Organic Chemistry and Biochemistry AS CR vvi, Deals By Therapy Area, 2012 to YTD 2018 8
Institute of Organic Chemistry and Biochemistry AS CR vvi, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Institute of Organic Chemistry and Biochemistry Enters into Co-Development Agreement with Johns Hopkins Medicine 10
Enamine Enters Into Co-Development Agreement With MRC LMB And IOCB For Rhomboid Protease Inhibitors 11
Dracen Pharma Enters into Licensing Agreement with Johns Hopkins University and Institute of Organic Chemistry 12
Institute of Organic Chemistry and Biochemistry AS CR vvi, Key Competitors 13
Institute of Organic Chemistry and Biochemistry AS CR vvi, Key Employees 14

List of Figures
Institute of Organic Chemistry and Biochemistry AS CR vvi, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Institute of Organic Chemistry and Biochemistry AS CR vvi, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Institute of Organic Chemistry and Biochemistry AS CR vvi, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Institute of Organic Chemistry and Biochemistry AS CR vvi, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Institute of Organic Chemistry and Biochemistry AS CR vvi, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Institute of Organic Chemistry and Biochemistry AS CR vvi, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Institute of Organic Chemistry and Biochemistry AS CR vvi, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Institute of Organic Chemistry and Biochemistry AS CR vvi, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

★海外企業調査レポート[Institute of Organic Chemistry and Biochemistry AS CR vvi:製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Petro Welt Technologies AG (O2C):企業の財務・戦略的SWOT分析
    Petro Welt Technologies AG (O2C) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and wea …
  • ifa systems AG (IS8):企業の財務・戦略的SWOT分析
    ifa systems AG (IS8) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …
  • General Motors Co (GM):企業の財務・戦略的SWOT分析
    General Motors Co (GM) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses an …
  • Ricoh Company, Ltd.:企業の戦略・SWOT・財務分析
    Ricoh Company, Ltd. - Strategy, SWOT and Corporate Finance Report Summary Ricoh Company, Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings a …
  • Enzo Biochem Inc (ENZ):企業の製品パイプライン分析
    Summary Enzo Biochem Inc (Enzo Biochem) is a life sciences and biotechnology company with a focus on harnessing genetic processes for the development of research tools, therapeutics and diagnostics. It also provides reference laboratory services to the medical community. The company focuses on the d …
  • Grupa Lotos SA (LTS)
    Grupa Lotos SA (LTS) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company
  • Koch Enterprises, Inc.:企業の戦略的SWOT分析
    Koch Enterprises, Inc. - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and …
  • Fujicco Co Ltd:企業の戦略・SWOT・財務情報
    Fujicco Co Ltd - Strategy, SWOT and Corporate Finance Report Summary Fujicco Co Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpora …
  • Regeneron Pharmaceuticals, Inc.:企業の戦略・SWOT・財務情報
    Regeneron Pharmaceuticals, Inc. - Strategy, SWOT and Corporate Finance Report Summary Regeneron Pharmaceuticals, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product …
  • Clean TeQ Holdings Ltd (CLQ):企業の財務・戦略的SWOT分析
    Summary Clean TeQ Holdings Ltd (Clean TeQ) is a clean technology company that offers air pollution control solutions using biotechnology-based processes. The company provides water treatment products such as advanced separations, advanced oxidation, encapsulated bacteria, continuous ionic filtration …
  • FieldPoint Petroleum Corp Oil & Gas Exploration and Production Operations and Cost Analysis – Q3, 2017
    FieldPoint Petroleum Corp Oil & Gas Exploration and Production Operations and Cost Analysis - Q3, 2017 Summary FieldPoint Petroleum Corp (FieldPoint) is an oil and gas company that acquires, operates and develops oil and gas properties. The company’s acquisition includes leasehold and working intere …
  • Seafarms Group Ltd (SFG):企業の財務・戦略的SWOT分析
    Seafarms Group Ltd (SFG) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses …
  • Suburban Propane Partners LP (SPH):企業の財務・戦略的SWOT分析
    Summary Suburban Propane Partners LP (Suburban Propane) distributes and markets energy-related products. The company supplies propane, fuel oil and refined fuels, and markets natural gas and electricity in deregulated markets. It also provides installation and service of various types of whole-house …
  • Tasly Pharmaceutical Group Co Ltd (600535):企業の財務・戦略的SWOT分析
    Tasly Pharmaceutical Group Co Ltd (600535) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengt …
  • Teleflex Inc (TFX):医療機器:M&Aディール及び事業提携情報
    Summary Teleflex Inc (Teleflex) designs, develops, manufactures, and distributes disposable medical devices for use in critical care and surgery. Its major products include circuits, masks and bags, endotracheal tubes, pain pumps, supraglottic airways, catheters, adaptor and connectors. The company’ …
  • Travis Perkins plc:企業の戦略・SWOT・財務分析
    Travis Perkins plc - Strategy, SWOT and Corporate Finance Report Summary Travis Perkins plc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and …
  • Jellagen Pty Ltd:医療機器:M&Aディール及び事業提携情報
    Summary Jellagen Pty Ltd (Jellagen) is a provider of medical grade collagen products. The company’s products offer medical grade collagen supplied in the form of hydragel used in wound dressing, soft tissue regeneration, tissue engineering and haemostats. Its product pipeline offer scaffolds, which …
  • Valener Inc (VNR)-エネルギー分野:企業M&A・提携分析
    Summary Valener Inc (Valener) is an investment holding company that focuses on the energy sector. Through its investment companies, the company offers storage, distribution, transportation and allied energy services. The company has interests in Gaz Metro and is its limited partner. Valener, through …
  • Cosmo Pharmaceuticals NV (COPN):製薬・医療:M&Aディール及び事業提携情報
    Summary Cosmo Pharmaceuticals NV (Cosmo) is a pharmaceutical company that develops drugs for the treatment of gastro-intestinal diseases. The company develops its pharmaceutical products based on its multi matrix technology. Its proprietary clinical development pipeline intended for the treatment of …
  • University of Texas Health Science Center at San Antonio-製薬・医療分野:企業M&A・提携分析
    Summary University of Texas Health Science Center at San Antonio (UTHSCSA), a subsidiary of University of Texas System is an educational university that offers undergraduate, graduate, and research programs to physicians, biomedical scientists, aging and longevity, cancer, cardiovascular, diabetes, …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆